LOS ANGELES — The novel phosphodiesterase 10A (PDE10A) inhibitor known as CPL'36 (Celon Pharma) is effective and generally safe in acute exacerbations of schizophrenia, new research suggested. In a ...
Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease. The Polish biotech tested two daily doses of the drug, dubbed CPL’36, in ...
-Company expects to initiate Phase 2 study in 2H 2025- SAN DIEGO, July 30, 2025 /PRNewswire/ -- EuMentis Therapeutics, Inc., ("EuMentis"), a clinical-stage drug development company focused on ...
NEWTON, MA, UNITED STATES, May 29, 2024 /EINPresswire.com/ -- EuMentis Therapeutics, Inc., a clinical stage drug development company focused on the development and ...
Statistically significant improvement in primary endpoint (UDysRS total scale) at Week 4 and positive benefit in the key secondary endpoint (UDysRS objective subscale), beginning at Day 7 Favorable ...
-Statistically significant benefit demonstrated in primary endpoint of positive subscale of the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) at Week 4- WARSAW, Poland, July 09, 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results